LON:AVCT Avacta Group (AVCT) Share Price, News & Analysis GBX 49 +2.50 (+5.38%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Avacta Group Stock (LON:AVCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avacta Group alerts:Sign Up Key Stats Today's Range 46.86▼ 51.9550-Day Range 44.20▼ 7052-Week Range 39.63▼ 143Volume2.16 million shsAverage Volume2.36 million shsMarket Capitalization£175.57 millionP/E RatioN/ADividend Yield3.97%Price TargetN/AConsensus RatingN/A Company OverviewAvacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More… Donald Trump can’t save you from this crisis (Ad)Elon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That’s why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?Get the full details now. Receive AVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address AVCT Stock News HeadlinesInvestors in Avacta Group (LON:AVCT) have seen splendid returns of 163% over the past five yearsNovember 13, 2024 | finance.yahoo.comAvacta Group Share Chat (AVCT)October 3, 2024 | lse.co.ukDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That’s why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?November 24, 2024 | Wide Moat Research (Ad)Avacta Group First Half 2024 Earnings: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)October 3, 2024 | uk.finance.yahoo.comAvacta Group Plc (AVCTF)July 27, 2024 | uk.finance.yahoo.comAvacta Group Plc reports FY resultsMay 1, 2024 | msn.comAvacta Group (LON:AVCT) investors are sitting on a loss of 82% if they invested three years agoMay 1, 2024 | finance.yahoo.comUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024March 6, 2024 | finance.yahoo.comSee More Headlines AVCT Stock Analysis - Frequently Asked Questions How have AVCT shares performed this year? Avacta Group's stock was trading at GBX 116.50 at the beginning of the year. Since then, AVCT shares have decreased by 57.9% and is now trading at GBX 49. View the best growth stocks for 2024 here. How were Avacta Group's earnings last quarter? Avacta Group Plc (LON:AVCT) released its quarterly earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) EPS for the quarter. Avacta Group had a negative trailing twelve-month return on equity of 73.02% and a negative net margin of 114.45%. How do I buy shares of Avacta Group? Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Avacta Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avacta Group investors own include Legal & General Group (LGEN), Lloyds Banking Group (LLOY), Lloyds Banking Group (LYG), IQE (IQE), Barclays (BARC), Meta Platforms (META) and Revvity (PKI). Company Calendar Last Earnings9/28/2020Today11/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:AVCT CUSIPN/A CIKN/A Webwww.avacta.com Phone+44-1904-217070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-25,890,000.00 Net Margins-114.45% Pretax MarginN/A Return on Equity-73.02% Return on Assets-21.80% Debt Debt-to-Equity Ratio63.54 Current Ratio1.29 Quick Ratio4.96 Sales & Book Value Annual Sales£22.62 million Price / Sales7.76 Cash FlowGBX 3.27 per share Price / Cash Flow15.00 Book ValueGBX 14 per share Price / Book3.50Miscellaneous Outstanding Shares358,300,000Free FloatN/AMarket Cap£175.57 million OptionableNot Optionable Beta1.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (LON:AVCT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.